The DIalysis Symptom COntrol-Restless Legs Syndrome (DISCO-RLS) Trial: A Protocol for a Randomized, Crossover, Placebo-Controlled Blinded Trial

David Collister, Kayla Pohl, Gwen Herrington, Shun Fu Lee, Christian Rabbat, Karthik Tennankore, Deborah Zimmermann, Navdeep Tangri, Ron Wald, Braden Manns, Rita S Suri, Annie-Claire Nadeau-Fredette, Remi Goupil, Samuel A Silver, Michael Walsh, David Collister, Kayla Pohl, Gwen Herrington, Shun Fu Lee, Christian Rabbat, Karthik Tennankore, Deborah Zimmermann, Navdeep Tangri, Ron Wald, Braden Manns, Rita S Suri, Annie-Claire Nadeau-Fredette, Remi Goupil, Samuel A Silver, Michael Walsh

Abstract

Background: Restless legs syndrome (RLS) affects approximately 30% of patients with end-stage kidney disease and is associated with impaired sleep and health-related quality of life. Medications used to treat RLS in patients receiving dialysis may have an increased risk of adverse events with dose titration, and residual RLS symptoms are common despite the use of effective treatments. Randomized controlled trials of monotherapy and combination pharmacologic therapy for RLS in hemodialysis are needed.

Objective: To perform a randomized, crossover, placebo-controlled blinded trial of pharmacologic therapy for RLS in hemodialysis.

Design/setting: The DIalysis Symptom COntrol-Restless Legs Syndrome (DISCO-RLS) trial is a randomized, crossover, placebo-controlled blinded trial of fixed low-dose pharmacologic therapy in patients receiving hemodialysis in 10 centers across Canada. It uses patient partners in its design, conduct, and reporting.

Participants: Adults receiving thrice-weekly hemodialysis for at least 3 months with RLS of at least mild symptoms defined International Restless Legs Syndrome Study Group Rating Scale (IRLS) of 10 or more will enter a double placebo run-in period to exclude nonadherent participants and those unable to tolerate double placebo. Seventy-two participants who completed the run-in period will be randomized to 1 of 8 treatment sequences based on modeling with 4 treatment periods.

Methods: Each treatment period lasts 4 weeks and consists of ropinirole 0.5 mg daily and gabapentin 100 mg daily, both together or neither with a double dummy placebo control for each treatment. The primary outcome is the difference in change scores of the IRLS between study treatments. Secondary outcomes are the differences in change scores of the Restless Legs Syndrome-6 Scale, patient global impression, 5-level EQ-5D version, and safety outcomes.

Results: This randomized, crossover, placebo-controlled blinded trial will evaluate the efficacy and safety of fixed low-dose combination of ropinirole and gabapentin in patients receiving hemodialysis with RLS.

Limitations: Patients with chronic kidney disease not on dialysis, kidney transplant recipients and those receiving peritoneal dialysis or home hemodialysis are not included. The intervention's long term safety and efficacy including the risk of augmentation is not captured.

Conclusion: This randomized crossover placebo controlled blinded trial will evaluate the efficacy and safety of fixed low-dose combination ropinirole and gabapentin in patients receiving hemodialysis with RLS.

Trial registration: ClinicalTrials.gov (NCT03806530).

Keywords: controlled trial; crossover; hemodialysis; randomized; restless legs syndrome.

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: D.C. is supported by a Kidney Research Scientist Core Education and National Training Program (KRESCENT) Post-doctoral Fellowship Award. S.A.S. is supported by a Kidney Research Scientist Core Education and National Training Program (KRESCENT) New Investigator Award. M.W. is supported by a Mid Career Investigator Award from McMaster University.

© The Author(s) 2020.

Figures

Figure 1.
Figure 1.
Study flowchart.
Figure 2.
Figure 2.
Hierarchical testing statistical analysis.

References

    1. Murtagh FE, Addington-Hall J, Higginson IJ. The prevalence of symptoms in end-stage renal disease: a systematic review. Adv Chronic Kidney Dis. 2007;14(1):82-99. doi:10.1053/j.ackd.2006.10.001.
    1. Weisbord SD, Fried LF, Mor MK, et al. Renal provider recognition of symptoms in patients on maintenance hemodialysis. Clin J Am Soc Nephrol. 2007;2(5):960-967.
    1. Mao S, Shen H, Huang S, Zhang A. Restless legs syndrome in dialysis patients: a meta-analysis. Sleep Med. 2014;15(12):1532-1538. doi:10.1016/j.sleep.2014.07.017.
    1. Mucsi I, Molnar MZ, Ambrus C, et al. Restless legs syndrome, insomnia and quality of life in patients on maintenance dialysis. Nephrol Dial Transplant. 2005;20(3):571-577. doi:10.1093/ndt/gfh654.
    1. Takaki J, Nishi T, Nangaku M, et al. Clinical and psychological aspects of restless legs syndrome in uremic patients on hemodialysis. Am J Kidney Dis. 2003;41(4):833-839. doi:10.1016/S0272-6386(03)00031-3.
    1. Unruh ML, Levey AS, D’Ambrosio C, et al. Restless legs symptoms among incident dialysis patients: association with lower quality of life and shorter survival. Am J Kidney Dis. 2004;43(5):900-909. doi:10.1053/j.ajkd.2004.01.013.
    1. La Manna G, Pizza F, Persici E, et al. Restless legs syndrome enhances cardiovascular risk and mortality in patients with end-stage kidney disease undergoing long-term haemodialysis treatment. Nephrol Dial Transplant. 2011;26(6):1976-1983. doi:10.1093/ndt/gfq681.
    1. Molnar MZ, Szentkiralyi A, Lindner A, et al. Restless legs syndrome and mortality in kidney transplant recipients. Am J Kidney Dis. 2007;50(5):813-820. doi:10.1053/j.ajkd.2007.08.003.
    1. Stefanidis I, Vainas A, Giannaki CD, et al. Restless legs syndrome does not affect 3-year mortality in hemodialysis patients. Sleep Medicine. 2015;16:1131-1138. doi:10.1016/j.sleep.2015.04.023.
    1. Allen RP, Picchietti DL, Garcia-Borreguero D, et al. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria—history, rationale, description, and significance. Sleep Med. 2014;15(8):860-873. doi:10.1016/j.sleep.2014.03.025.
    1. Manns B, Hemmelgarn B, Lillie E, et al. Setting research priorities for patients on or nearing dialysis. Clin J Am Soc Nephrol. 2014;9:1813-1821. doi:10.2215/CJN.01610214.
    1. Gopaluni S, Sherif M, Ahmadouk NA. Interventions for chronic kidney disease-associated restless legs syndrome. The Cochrane Database of Systematic Reviews. 2016;11:CD010690. doi:10.1002/14651858.CD010690.pub2.
    1. Collister D, Rodrigues JC, Mazzetti A, et al. Screening questions for the diagnosis of restless legs syndrome in hemodialysis. Clin Kidney J. 2018;12:559-563. doi:10.1093/ckj/sfy129.
    1. Hornyak M, Trenkwalder C, Kohnen R, Scholz H. Efficacy and safety of dopamine agonists in restless legs syndrome. Sleep Med. 2012;13(3):228-236. doi:10.1016/j.sleep.2011.09.013.
    1. Allen RP, Chen C, Garcia-Borreguero D, et al. Comparison of pregabalin with pramipexole for restless legs syndrome. New Engl J Med. 2014;370:621-631. doi:10.1056/NEJMoa1303646.
    1. Giannaki CD, Sakkas GK, Karatzaferi C, et al. Effect of exercise training and dopamine agonists in patients with uremic restless legs syndrome: a six-month randomized, partially double-blind, placebo-controlled comparative study. BMC Nephrol. 2013;14:194. doi:10.1186/1471-2369-14-194.
    1. Miranda M, Kagi M, Fabres L, et al. Pramipexole for the treatment of uremic restless legs in patients undergoing hemodialysis. Neurology. 2004;62:831-832.
    1. Pieta J, Millar T, Zacharias J, et al. Effect of pergolide on restless legs and leg movements in sleep in uremic patients. Sleep. 1998;21:617-622.
    1. Thorp ML, Morris CD, Bagby SP. A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients. Am J Kidney Dis. 2001;38(1):104-108. doi:10.1053/ajkd.2001.25202.
    1. Liu GJ, Wu L, Wang SL, et al. Incidence of augmentation in primary restless legs syndrome patients may not be that high: evidence from a systematic review and meta-analysis. Medicine. 2016;95:e2504. doi:10.1097/MD.0000000000002504.
    1. Ishida JH, McCulloch CE, Steinman MA, Grimes BA, Johansen KL. Gabapentin and pregabalin use and association with adverse outcomes among hemodialysis patients. J Am Soc Nephrol. 2018;29(7):1970-1978. doi:10.1681/asn.2018010096.
    1. Levin A, Adams E, Barrett BJ, et al. Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney Disease (Can-SOLVE CKD): form and function. Can J Kidney Health Dis. 2018;5. doi:10.1177/2054358117749530.
    1. Kohnen R, Martinez-Martin P, Benes H, et al. Rating of daytime and nighttime symptoms in RLS: validation of the RLS-6 scale of restless legs syndrome/Willis-Ekbom disease. Sleep Med. 2016;20:116-122. doi:10.1016/j.sleep.2015.10.014.
    1. GarcÃ-a-Borreguero D, Allen RP, Kohnen R, et al. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med 2007;8(5):520-530. doi:10.1016/j.sleep.2007.03.022.
    1. Walters AS, LeBrocq C, Dhar A, et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Medicine. 2003;4:121-132. doi:S1389945702002587.
    1. Allen R, Oertel W, Walters A, et al. Relation of the International Restless Legs Syndrome Study Group rating scale with the Clinical Global Impression severity scale, the restless legs syndrome 6-item questionnaire, and the restless legs syndrome-quality of life questionnaire. Sleep Med. 2013;14(12):1375-1380. doi:10.1016/j.sleep.2013.09.008.
    1. Allen RP. Minimal clinically significant change for the International Restless Legs Syndrome Study Group rating scale in clinical trials is a score of 3. Sleep Med. 2013;14(11):1229. doi:10.1016/j.sleep.2013.08.001.
    1. Lee SF, Bangdiwala SI, Spence J, Connolly S. When and how should we cluster and cross over: methodological and ethical issues (letter 2). Can J Anaesth. 2019;66(2):237-238.
    1. Dmitrienko A, Offen WW, Westfall PH. Gatekeeping strategies for clinical trials that do not require all primary effects to be significant. Stat Med. 2003;22:2387-2400. doi:10.1002/sim.1526.
    1. Kaye CM, Nicholls B. Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet. 2000;39:243-254. doi:10.2165/00003088-200039040.
    1. Blum RA, Comstock TJ, Sica DA, et al. Pharmacokinetics of gabapentin in subjects with various degrees of renal function. Clin Pharmacol Ther. 1994;56(2):154-159.
    1. Wong MO, Eldon MA, Keane WF, et al. Disposition of gabapentin in anuric subjects on hemodialysis. J Clin Pharmacol. 1995;35(6):622-626.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe